从循证证据看德谷胰岛素利拉鲁肽注射液的临床应用  

Clinical Application of Insulin Degludec and Liraglutide Injection Based on Evidence-based Medicine

作　　者：朱大龙[1] ZHU Dalong(Drum Tower Hospital Affiliated to Nanjing University Medical School,Nanjing Jiangsu 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院,江苏南京210008

出　　处：《药品评价》2023年第6期655-660,共6页Drug Evaluation

摘　　要：基础胰岛素与胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)联合用药是近十年糖尿病注射疗法的重要进展之一。新型降糖药物德谷胰岛素利拉鲁肽注射液(Insulin Degludec and Liraglutide Injection,IDegLira)将基础胰岛素类似物(德谷胰岛素)与GLP-1RA受体激动剂(利拉鲁肽)两种药物联合,2022年进入中国市场。现依据IDegLira发表的相关循证证据,介绍作用机制、药效/药代动力学,并且从循证医学角度列举在不同2型糖尿病人群的疗效和安全性及其真实世界研究结果,以帮助临床医生全面了解IDegLira。The combinational use of basal insulin and glucagon-like peptide-1 receptor agonist(GLP-1RA)is one of the progression landmark in the injection formulation of diabetes in the past decade.In 2022,as the first fixed-ratio combination formula of basal insulin analogue(insulin Degludec)and GLP-1RA(Liraglutide),IDegLira entered the Chinese market.This review takes some clinical evidences of IDegLira to introduce the mechanism of action,pharmacodynamics/pharmacokinetics,efficacy,safety of different population with type 2 diabetes and results of real-world research from the perspective of evidencebased medicine,so as to favor physicians to fully understand the clinical application of this drugs.

关 键 词：糖尿病 2型 德谷胰岛素利拉鲁肽注射液 胰高血糖素样肽-1受体 研究进展 临床应用 

分 类 号：R977.15[医药卫生—药品]